New York State Teachers Retirement System Has $16.30 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

New York State Teachers Retirement System decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 8.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 219,527 shares of the medical equipment provider’s stock after selling 20,286 shares during the quarter. New York State Teachers Retirement System owned about 0.09% of Hologic worth $16,300,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. iA Global Asset Management Inc. bought a new position in shares of Hologic during the 1st quarter valued at $37,000. Mather Group LLC. bought a new stake in Hologic in the first quarter valued at about $48,000. Massmutual Trust Co. FSB ADV grew its stake in shares of Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares during the period. Toth Financial Advisory Corp boosted its stake in Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 347 shares in the last quarter. Finally, Fidelis Capital Partners LLC acquired a new position in Hologic during the first quarter worth $63,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 0.1 %

HOLX traded down $0.08 during trading on Friday, reaching $80.01. 534,466 shares of the company’s stock were exchanged, compared to its average volume of 1,644,897. The company’s fifty day moving average price is $77.58 and its 200-day moving average price is $76.07. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.29 and a current ratio of 3.99. The firm has a market capitalization of $18.67 billion, a PE ratio of 40.86, a P/E/G ratio of 2.64 and a beta of 0.99. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.93 earnings per share. As a group, equities analysts forecast that Hologic, Inc. will post 4.08 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on HOLX shares. JPMorgan Chase & Co. increased their target price on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 10th. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Finally, Stephens reissued an “overweight” rating and set a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

Insider Activity at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.